Key Points:
- Upadacitinib has been shown to improve symptoms like soft/liquid stool frequency (SF) and abdominal pain scores (APS) within the first week of treatment in patients with moderate to severe Crohn’s disease.
- The findings are based on a post hoc analysis of data from two phase 3 12-week induction trials, U-EXCEL and U-EXCEED. These trials included patients with and without prior biologic failure.
- The study involved 1021 patients aged 18-75 years, all of whom had a daily very soft or liquid SF of ≥ 4 and APS of ≥ 2.
- Participants received either once-daily 45 mg upadacitinib (674 patients) or a placebo (347 patients).